Name: UMIN ID:
Unique ID issued by UMIN | UMIN000030495 |
---|---|
Receipt number | R000034813 |
Scientific Title | An exploratory study to determine the genetic polymorphisms or mutations associated with type 1 diabetes and interstitial lung disease induced by immune checkpoint inhibitor; nivolumab |
Date of disclosure of the study information | 2017/12/21 |
Last modified on | 2021/07/02 17:00:22 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2017/12/20 19:04:36 | ||
2 | Update | 2018/07/04 18:38:26 | Other related information Other related information |
|
3 | Update | 2018/07/04 18:40:21 | Recruitment status |
|
4 | Update | 2018/12/24 14:27:49 | Organization Co-sponsor Co-sponsor |
|
5 | Update | 2019/10/28 19:55:51 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Last name of contact person Last name of contact person Zip code Organization Co-sponsor Co-sponsor Organization Organization Address Address Tel |
|
6 | Update | 2019/10/28 20:00:58 | Date of IRB Last follow-up date |
|
7 | Update | 2019/12/27 15:55:48 | Key inclusion criteria Key inclusion criteria Target sample size |
|
8 | Update | 2019/12/27 16:00:14 | Co-sponsor |
|
9 | Update | 2019/12/27 16:05:08 | Date analysis concluded |
|
10 | Update | 2019/12/27 16:06:02 | Date trial data considered complete |
|
11 | Update | 2021/01/03 17:35:02 | Last follow-up date Date of closure to data entry Date trial data considered complete Date analysis concluded |
|
12 | Update | 2021/07/02 16:57:52 | Key inclusion criteria Key inclusion criteria |
|
13 | Update | 2021/07/02 17:00:22 | Date analysis concluded |